Our pipeline currently centers on two promising compounds developed by world renowned Professors’ Chang and Han.
This platform drug as shown promise for the treatment of Acute Myeloid Leukemia. Formally known as TPA, this platform small molecule has many potential therapeutic uses. Rich Pharmaceuticals is exploring multiple indications for the highest likelihood of commercialization success that has the potential to become new compelling treatments for patients.
Rich Pharmaceuticals To Launch CannCodex, marking its entry into Medicinal Cannabis Industry
Rich Pharmaceuticals Attracts New Financing Package with GHS Investments, LLC
Rich Pharmaceuticals, Inc. Announces Quarterly Milestones